Ageas: Close of AG insurance 25% acquisition from BNPP, BNPP stake in Group capped. dsm-firmenich: Symrise 1Q26 IMS better than expected. KPN: 1Q26 better EBITDAal despite slight services sales miss, guidance reiterated. Lotus Bakeries: peer Mondelez 1Q26 results. Melexis: 1Q26 results, no surprises. MICC: peer Mondelez 1Q26 results. Ontex: A weak start to the year. Shell: Addition to grow faster in hydrocarbons. Universal Music Group: Spotify 1Q26 results good, ad supported and ...
Galapagos’ Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders’ Meetings 2026 Mechelen, Belgium; April 28, 2026, 22:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG) today announces that all resolutions proposed at the Company’s Annual and Extraordinary Shareholders’ Meetings (AGM and EGM) held on 28 April 2026 were approved. The AGM approved, amongst other items: The Annual Report and the Remuneration ReportThe remuneration of the members of the Board of DirectorsThe appointment of Mr. Henry Gosebruch as Executive DirectorThe a...
Aandeelhouders van Galapagos keuren alle door de Raad van Bestuur voorgestelde besluiten goed op de Gewone en Buitengewone Algemene Vergaderingen van 2026 Mechelen, België; 28 april 2026, 22:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG) maakt vandaag bekend dat alle voorstellen tot besluit op de Gewone en Buitengewone Algemene Vergaderingen (GAV en BAV) van 28 april 2026 zijn goedgekeurd. De Gewone Algemene Vergadering keurde onder meer goed: Het jaarverslag en het remuneratieverslagDe bezoldiging van de leden van de Raad van BestuurDe benoeming van Mr. Henry Gosebruch tot Uitvoerend B...
Coca-Cola Europacific Partners: Easter bunny. dsm-firmenich: No Pin, No Gain. D'Ieteren: Belgian competitor Autoglass Clinic doubles in size since acquisition by Cary. PostNL: 1Q26 trading disappoints on weak volume trends; FY26 outlook reiterated. Theon International: Preview – up for a solid start
Weekly progress on share repurchase program to cover share plans and reduce capital Press Release Weekly progress on share repurchase program to cover share plans and reduce capital Kaiseraugst (Switzerland), Maastricht (Netherlands), April 28, 2026 dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 9, 2026 its intention to repurchase ordinary shares with an aggregate market value of €500 million and reduce its issued capital. On March 12, 2026, the company commenced repurchasing ordinary shares for a total amount of €540 million, of which €40 million to co...
A director at Umicore S.A. sold 2,739 shares at 17.990EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
AkzoNobel: 1Q26 beat and FY guidance maintained. ASM International: 1Q26 results, great start to the year. Basic-Fit: Highlights of Capital Markets Day 2026. BE Semiconductor Industries: 1Q26 Preview - building strength. Cofinimmo: Earnings beat, muted investments; Armonea agreement reached. Corbion: Not so sweet. MICC: Peer Danone 1Q26 results. Randstad: Slight beat on 1Q26, trends improving; 2Q26 guidance at least in line. Recticel: 1Q26 in line, sharp pick-up expected in 2Q. ...
Weekly progress on share repurchase program to cover share plans and reduce capital Press Release Weekly progress on share repurchase program to cover share plans and reduce capital Kaiseraugst (Switzerland), Maastricht (Netherlands), April 21, 2026 dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 9, 2026 its intention to repurchase ordinary shares with an aggregate market value of €500 million and reduce its issued capital. On March 12, 2026, the company commenced repurchasing ordinary shares for a total amount of €540 million, of which €40 million to co...
UCB announced that it has entered into a definitive agreement to acquire Neurona Therapeutics, including lead epilepsy cell therapy asset NRTX-1001, for a $ 650m upfront and up to $ 500m in potential milestones. We're encouraged by NRTX-1001's phase 1/2 data showing approx. 80% reduction in disabling seizures at 4-6 months post administration in drug-resistant unilateral mesial temporal lobe epilepsy (MTLE), with or without mesial temporal sclerosis (MTS), and look forward to the phase 3 progra...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.